iRhythm Holdings (NASDAQ:IRTC) is among the top 12 medical devices stocks to invest in according to Hedge Funds. Morgan Stanley maintains an Overweight rating on IRTC with a price target of $205, representing a 35% upside. The company’s preliminary fourth-quarter results exceeded consensus estimates, with revenues around $207 million.

Vijay Kumar from Evercore ISI revised his rating for iRhythm Holdings (NASDAQ:IRTC) to Outperform with a price target of $210, offering a potential upside of over 38%. IRTC develops Zio biosensor technology for cardiac arrhythmia diagnosis and offers long-term and short-term cardiac monitoring services, incorporating AI-based data analytics.

With a focus on AI stocks with greater upside potential and less downside risk, iRhythm Holdings (NASDAQ:IRTC) remains a promising investment. The company’s 2026 guidance projects midpoint revenues around $875 million, excluding expected numbers from its next-generation Mobile Cardiac Telemetry device. For more insights on AI stocks, see the free report on the best short-term AI stock.

Read more at Yahoo Finance: Here is Why Hedge Funds Are Appreciating iRhythm Holdings (IRTC)